| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Glucosamine (GlcN) is widely used as a dietary supplement to treat osteoarthritis (OA) in humans. An anti-inflammatory action of GlcN is speculated to be involved in its protective actions on OA. However, its precise mechanism is not clear. In this research project, we examined the molecular mechanisms of GlcN for anti-inflammatory action in synovial cells. GlcN induced the O-N-acetylglucosamine (O-GlcNAc) modification of cellular proteins, and transcription factor Sp1 was identified as O-GlcNAc modified protein by GlcN. Sp1 was involved in the regulation of IL-8 production. Furthermore, GlcN moderated transcription activity of Sp1 and intranuclear amount of Sp1 via the O-GlcNAc modification. Together these observations suggest that GlcN alleviates synovial inflammation by the suppression of proinflammatory cytokines, such as IL-8, via O-GlcNAc modification of Sp1.
|
